Intensive glucose lowering made little or no difference to new diabetic neuropathy

Design

Systematic review and meta-analysis of randomised trials

Population

9 trials in adults with type 2 diabetes

Primary outcome

Incident diabetic peripheral neuropathy

Effect

Glycaemic control OR 0.93 (95% CI 0.85 to 1.02) after excluding BARI-2D

A meta-analysis gathered randomised trials of interventions on modifiable risk factors for preventing peripheral neuropathy in type 2 diabetes. Nine trials had usable data, most at low risk of bias.

Across five glycaemic trials, intensive control did not clearly reduce neuropathy (OR 0.89, 95% CI 0.66 to 1.19), with high heterogeneity. Removing BARI-2D, which compared drug strategies rather than glucose targets, left an OR of 0.93 (0.85 to 1.02). Within BARI-2D, an insulin-sensitising strategy was linked to less neuropathy independent of HbA1c (0.84, 0.71 to 0.99). Single trials hinted at benefit from blood pressure lowering and multifactorial care, at low certainty.

This challenges the habit of telling patients that tighter glucose control will protect their feet. Glucose control matters for other reasons, but for neuropathy the evidence leans towards a broader approach.

• Do not promise patients that tighter HbA1c alone will prevent neuropathy
• Treat blood pressure, lipids and smoking alongside glucose; multifactorial care may help nerves too
• Keep annual foot examination with monofilament testing for everyone with type 2 diabetes
• Avoid chasing very low HbA1c targets in frail patients for neuropathy prevention alone

Why it matters

It questions a standard counselling line in diabetes clinics.

Don't overread it

The BARI-2D drug-class finding is one trial in patients with coronary disease and needs replication.

The statistics, in plain English

The four-trial estimate (0.93, 0.85 to 1.02) is precise and sits close to 1, so any benefit is probably small. The blood pressure and multifactorial signals come from single trials and are low certainty.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.